Based on the aggregated intelligence of 135,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Cardiome Pharma Corp. (Nasdaq: CRME ) , which develops drugs to treat cardiovascular diseases, has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Cardiome's business and see what CAPS investors are saying about the stock right now.
Cardiome facts
|
Headquarters
|
Vancouver, Canada (1986)
|
|
Market Cap
|
$267.9 million
|
|
Industry
|
Pharmaceuticals
|
|
TTM Revenue
|
$9 million
|
|
Management
|
CEO Douglas Janzen (newly appointed)
CFO Curtis Sikorsky
|
|
Cash/Debt
|
$70.5 million/$0
|
|
Strategic Alliances
|
Genzyme (Nasdaq: GENZ )
Merck (NYSE: MRK )
|
|
CAPS Members Bullish on CRME Also Bullish on:
|
Johnson & Johnson (NYSE: JNJ )
Apple (Nasdaq: AAPL )
|
|
CAPS Members Bearish on CRME Also Bearish on:
|
Canadian Solar (Nasdaq: CSIQ )
|
Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS. TTM = trailing 12 months.
Over on CAPS, 155 of the 164 members who have rated Cardiome -- some 94.5% -- believe the stock will outperform the S&P 500 going forward. These bulls include All-Stars zzlangerhans and mrindependent, both of whom are ranked in the top 3% of our community.
Late last year, zzlangerhans touched on the heart pressures associated with the stock (at a much higher price point, to boot):
While the process is certainly frustrating for impatient investors, the eventual payoff is likely to be very high. ... The bottom line is that the vernakalant data is good, the need for the drug is certainly there, and there's definitely potential for it to be a game changer in the emergency management of atrial fibrillation.
In a more recent pitch from three days ago, mrindependent elaborates:
This play is speculative because the company has no dependable earnings history and the balance sheet is mediocre. BUT the company does have a binding contract with Merck for the development and commercialization of Vernakalant, a treatment for atrial fibrillation. The $60 million initial payment from Merck shows that the agreement is very significant. This stock has significant upside.
What do you think about Cardiome, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 135,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.
RSS Headlines
Fool UK